Jun 26 | 04:10 IST
Will the Lancet study be the wake-up call India needs on public health?
Need more than just generic drug prescriptions
Chandrababu Naidu's revenue challenge in Andhra
Post Jayalalithaa: Industry expects medium-term continuity but long-term concerns remain
Are you sure the medicine you are consuming is at the right price?
Celebrate good rains but watch out for monsoon-related infections
A Scientist's Take On Competing In A Free Market
Politics over Economics: Musings of a Pioneer
Who owns water and other questions
GSK shows a 'human face' but access of medicines to remain a challenge
Zika, the new buzzword
The passing away of a strategic developer
Did a red herring over drug safety put paid to India's first new drug?
National mission of US is to cure cancer. What is ours?
Dealing with drugs that don't work
Year after Chhattisgarh sterilisation deaths, review still on
Is USFDA shifting its focus to APIs and injectables?
Pharma's bad practices take new forms
A year later, no lessons learnt: Dengue, Swine Flu hurt India again
PM Modi at UN, hope India sticks to the goals on saving lives
Good time to invest in emerging markets
What Indian pharma research must learn from Sun Pharma's Glaucoma drug experience
EU ban hits Indian pharma hard
Tracking system a start, but more needed to ensure Indian drug quality
For Telangana and Andhra, endemic diseases remain a challenge
In India, roads often lead to the casualty ward
Indian Pharma industry's Oliver syndrome
The importance of B.P.R. Vithal
Andhra-Telangana PSU split: Same yardstick may not work for all
Slowdown in drug approvals, currency volatility a test for pharma companies